Spots Global Cancer Trial Database for Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Official Title: An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
Study ID: NCT04586660
Conditions
Interventions
Study Description
Brief Summary: The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).
Detailed Description:
Eligibility
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Jishuitan Hospital, Beijing, Beijing, China
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
The Third Affiliated Hospital Of Southern Medical University, Guangzhou, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Harbin Meidical University Cancer Hospital, Harbin, Heilongjiang, China
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Peking University Peoples Hospital, Beijing, , China
National Taiwan University Hospital, Taipei, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
